Bexorg Appoints Mikael Dolsten as Board Chairman
The New Haven biotech firm separates leadership roles to support the development of its precision neurology platform.
Updated on Oct. 27, 2026 in People
Bexorg has appointed industry veteran Mikael Dolsten as the new Chairman of its Board of Directors. The leadership transition, which coincides with the retirement of director Jon Faiz Kayyem, separates the roles of Chairman and CEO for the company.
Why it matters
The appointment aims to accelerate the growth of the company's BrainEx platform and the development of its proprietary drug portfolio. Separating the roles is a strategic shift to better support the firm's current expansion phase.
New Chairman Mikael Dolsten brings three decades of drug discovery experience to the board. He previously oversaw the development of 36 medicines and vaccines that secured regulatory approval.
The players
Mikael Dolsten
He is the newly appointed Chairman of Bexorg who previously served as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer.
Zvonimir Vrselja
He serves as the CEO and a board member of Bexorg and managed the separation of the company's Chairman and CEO roles.
Jon Faiz Kayyem
He is a former independent director of the Bexorg board who recently retired from his position.
The details
Bexorg operates a specialized precision neurology platform that utilizes human brain tissue combined with AI models. CEO Zvonimir Vrselja continues to lead the company while focusing on building its internal pipeline.
Timeline
The board leadership changes became effective on October 27, 2026.
Market Landscape
This transition aligns with the industry-standard governance practice of separating the CEO and Chairman roles to increase board oversight. It positions Bexorg to better manage the complexities of transitioning from an research-focused startup to a commercial drug developer.
This leadership shift primarily impacts investors and stakeholders who monitor the firm's strategic direction. Customers and partners should expect no immediate changes to daily operations or service availability at the New Haven facility.
The takeaway
Separating executive leadership roles often signals that a company is preparing for a new stage of operational maturity. Investors typically view this as a commitment to stronger internal governance and focused research output.
Further reading
For more information on executive changes in the region, visit the People section.
Source note: This article includes information reported by The Manila times.
